Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 1998

View Archived Issues

biosyn Arzneimittel seeks licensees for its oncolytic products

Introgen reports results of phase I/II adenoviral-p53 gene therapy trial

Vaccine carrier offered for licensing by biosyn Arzneimittel

SangStat receives U.S. patent covering multiple ciclosporin formulations

Celtrix's SomatoKine shows promise in treating protein wasting

BioTime's PentaLyte reduces hypovolemic injury in preclinical study

MMP-2 and MMP-3 inhibitors identified at Warner-Lambert

Lilly continues R&D focus on compounds for postmenopausal syndrome

Novel trpS polypeptides/polynucleotides for the treatment of bacterial infections

Phase I trial results presented for perillyl alcohol

Supplemental NDA filed for Rebetron combination therapy

Elinafide, a potent antitumor agent plagued by significant toxicities

Cypros begins pivotal phase III trial with Cordox

FDA accepts IND to test ADL-2-1294 for relief of corneal pain

Neose Technologies and Bristol-Myers Squibb collaborate on oncologic vaccines

ICO25 MAb suppresses tumor growth and prolongs survival in preclinical model of colon cancer

Harvard Scientific acquires rights to oral treatment for sexual dysfunction

New fluorinated anthracyclines from M.D. Anderson

Sugen to initiate expanded trials of SU-5416 in U.S. and Europe

Hoe-901: new long-acting insulin for IDDM and NIDDM

CereXus formed to study sodium channel blockers

Brain-selective potassium channel ligands synthesized at Bayer

Pharmachemie discovers new paclitaxel prodrugs for use in ADEPT

MD-700, a new LDL receptor-upregulating compound from Taisho

Shock reported following substitution of mibefradil with other calcium channel blockers

CBER requests additional information for Ontak BLA

EXO-226 effective against diabetic nephropathy in db/db mice

Sibutramine: preclinical effects on glucose homeostasis and uptake

New agent for rheumatoid arthritis in development by Toray and Kaken

Orlistat reaches first market

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...